Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hospira Healthcare India Pvt. Ltd.
WARNING LETTER
•Hospira Healthcare India Pvt. Ltd.•October 10, 2012

Hospira Healthcare India Pvt. Ltd. – FDA Warning Letter, Oct 10, 2012

Record Details

An FDA inspection conducted from October 3-10, 2012, at Hospira Healthcare India Pvt., Ltd. in India, identified significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR Parts 210 and 211). These deviations render the firm's drug products adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The firm's response was deemed to lack sufficient corrective actions.

Key violations include the failure to establish and follow appropriate written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes (21 CFR 211.113(b)). Specific issues noted were inadequate sanitization, improper aseptic interventions, lack of dynamic airflow studies, insufficient media fill batch records, and compromised glove sterility. Additionally, the firm failed to maintain facilities of appropriate construction to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)), evidenced by holes between classified areas and an inadequately designed entry/exit door affecting airflow.

FDA requires a written response within fifteen working days detailing specific corrective and preventative actions, along with supporting documentation. Failure to correct these violations may result in FDA withholding approval of new applications and refusing admission of articles manufactured at the facility into the United States. The letter also advises contacting the Drug Shortages Program if production is reduced.

Company
Hospira Healthcare India Pvt. Ltd.
Inspection date
October 10, 2012
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Michael D. Smedley
View Company Profile

ID · adac5f56-8000-4802-b8ef-82354c1f1aad

Violation Codes9
21 CFR 21021 CFR 21121 CFR 211.113(b)21 CFR 211.42(a)21 U.S.C. 381(a)(3)21 U.S.C. 356C(a)(1)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Hospira Healthcare India Pvt. Ltd.
  • WARNING_LETTER - 2018-04-03April 3, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira Healthcare India Pvt. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.